rt-PA和尿激酶溶栓治疗急性脑梗死的临床前瞻性研究  

Clinical prospective study on intra-arterial thrombolysis with rt-PA and urokinase for acute cerebral infarction

作　　者：田洪[1] 张玉波[1] 牟长河[1] 刘磊[1] 

机构地区：[1]解放军324医院神经内科,重庆400020

出　　处：《西南国防医药》2011年第9期940-942,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的比较重组组织型纤溶酶原激活剂(rt-PA)和尿激酶动脉溶栓治疗急性脑梗死的疗效和安全性。方法分别采用rt-PA和尿激酶对63例急性脑梗死患者进行动脉溶栓,分析评价其临床疗效及不良反应。结果 63例脑梗死均为颈内动脉系统闭塞,动脉溶栓后,两组患者血管再通率、临床显效率和脑水肿的发生率比较无明显差异(P>0.05);rt-PA组颅内出血发生率11.1%明显小于尿激酶组39.4%(P<0.05)。结论 rt-PA动脉溶栓治疗急性脑梗死的安全性优于尿激酶,临床疗效及再通率与尿激酶相似。Objective To investigate the efficacy and safety of intra-arterial thrombolysis with urokinase and recombinant tissue plasminogen activator（rt-PA）for the treatment of acute cerebral infarction.Methods rt-PA and urokinase were used respectively in intra-arterial thrombolysis for 63 patients with acute cerebral infarction,and their clinical efficacy and adverse reactions were evaluated.Results All of the 63 patients with cerebral infarction were internal carotid artery occlusion.There were no significant differences in revascularization rate,improving rate and cerebral edema incidence between the two groups after intra-arterial thrombolysis（P〉0.05）.The intracranial hemorrhage rate in the rt-PA group was smaller than that in the urokinase group（11.1% versus 39.4%,P〈0.05）.Conclusion The safety of intra-arterial thrombolysis with rt-PA for acute cerebral infarction is better than that with urokinase,but the clinical efficacy and revascularization rate are similar in both.

关 键 词：脑梗死 动脉溶栓 重组组织型纤溶酶原激活剂 尿激酶 

分 类 号：R743.32[医药卫生—神经病学与精神病学]